

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	6183829
<b>Application Number:</b>	10555345
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	4521
<b>Title of Invention:</b>	Method of Reducing Nosocomial Infections
<b>First Named Inventor/Applicant Name:</b>	David Barshis
<b>Customer Number:</b>	32692
<b>Filer:</b>	Nancy M. Lambert/Judy Hansen
<b>Filer Authorized By:</b>	Nancy M. Lambert
<b>Attorney Docket Number:</b>	63365US008
<b>Receipt Date:</b>	01-OCT-2009
<b>Filing Date:</b>	16-APR-2008
<b>Time Stamp:</b>	12:20:18
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Filed (SB/08)	IDS_3_w-1449_63365US008. PDF	1597633  c3e3bf959235809c9918ab54ea29144f988a7a75	no	3

### Warnings:

### Information:

This is not an USPTO supplied IDS fillable form					
2	NPL Documents	Hospital_slashes_pneumonia_rate_etc.PDF	981105 d9e66c1428c74a1d44e634bc57080f95c1d84af	no	3
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	Houston_S_etal_Effectiveness_of_0_12_Chlorhexidine_etc.PDF	4990003 864f9b7a8b80327040cd5ee8bf29bb576051bed	no	5
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	DeRiso_A_etal_Chlorhexidine_Gluconate_etc.PDF	7441173 50cd5babb9b096447f6001a83ee3a04bb470f69	no	8
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	Genuit_T_etal_Prophylactic_Chlorhexidine_Oral_etc.PDF	13698192 1106239f7409b5a1ce6534ada5165473f8fb578	no	15
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	Clinical_Strategy_Watch.PDF	4517752 439608f6cde578f59d245e8b47aea37438f7ac1b	no	5
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			33225858		
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>  If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>  If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>  If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					